MedAvail Holdings (STU:73M) ROE %: -169.92% (As of Jun. 2023)


STU:73M MedAvail Holdings Inc STU:73M
12 GF Score
Price €11.05
View Full Analysis

What is MedAvail Holdings ROE %?

MedAvail Holdings STU:73M 12 ROE % is -169.92% as of Jun. 2023. GuruFocus rates STU:73M with a GF Score™ of 12/100.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. MedAvail Holdings's annualized net income for the quarter that ended in Jun. 2023 was €-21.38 Mil. MedAvail Holdings's average Total Stockholders Equity over the quarter that ended in Jun. 2023 was €12.58 Mil. Therefore, MedAvail Holdings's annualized ROE % for the quarter that ended in Jun. 2023 was -169.92%.

The historical rank and industry rank for MedAvail Holdings's ROE % or its related term are showing as below:

STU:73M's ROE % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 5.84
* Ranked among companies with meaningful ROE % only.

MedAvail Holdings  (STU:73M) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=-21.38/12.5825
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-21.38 / 1.496)*(1.496 / 30.481)*(30.481 / 12.5825)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1429.14 %*0.0491*2.4225
=ROA %*Equity Multiplier
=-70.17 %*2.4225
=-169.92 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=-21.38/12.5825
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-21.38 / -20.292) * (-20.292 / -16.444) * (-16.444 / 1.496) * (1.496 / 30.481) * (30.481 / 12.5825)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0536 * 1.234 * -1099.2 % * 0.0491 * 2.4225
=-169.92 %

Note: The net income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


MedAvail Holdings ROE % Related Terms


MedAvail Holdings ROE % Historical Data

* Premium members only.

The historical data trend for MedAvail Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedAvail Holdings ROE % Chart

MedAvail Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22
ROE %
0.00 0.00 -115.62 -246.05

MedAvail Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -239.53 -152.30 -163.04 -549.80 -169.92

STU:73M vs HEWA, BIMI, MEDS: ROE % Comparison

For the Pharmaceutical Retailers subindustry, MedAvail Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedAvail Holdings ROE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MedAvail Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where MedAvail Holdings's ROE % falls into.


STU:73M
12GF Score
MedAvail Holdings Inc STU:73M
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MedAvail Holdings ROE % Calculation

MedAvail Holdings's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-44.95/( (16.88+19.658)/ 2 )
=-44.95/18.269
=-246.05 %

MedAvail Holdings's annualized ROE % for the quarter that ended in Jun. 2023 is calculated as

ROE %=Net Income (Q: Jun. 2023 )/( (Total Stockholders Equity (Q: Mar. 2023 )+Total Stockholders Equity (Q: Jun. 2023 ))/ count )
=-21.38/( (3.894+21.271)/ 2 )
=-21.38/12.5825
=-169.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2023) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of -169.92% mean?
MedAvail Holdings (STU:73M) has a ROE % of -169.92% as of Jun. 2023. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on MedAvail Holdings and its competitors.
Is MedAvail Holdings' ROE % too high?
MedAvail Holdings' current ROE % is -169.92%. Overall, MedAvail Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does MedAvail Holdings' ROE % compare to HEWA and BIMI?
MedAvail Holdings' ROE % of -169.92% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROE % is 5.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.84, based on 625 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on MedAvail Holdings and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedAvail Holdings's current ROE % is -169.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedAvail Holdings stock overvalued right now?
MedAvail Holdings (STU:73M) has a current ROE % of -169.92%. The current ROE % is -169.92%. MedAvail Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For MedAvail Holdings (STU:73M), the current ROE % is -169.92% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedAvail Holdings Business Description

Address 4720 East Cotton Gin Loop, Suite 220, Phoenix, AZ, USA, 85040
MedAvail Holdings Inc is a telehealth-enabled pharmacy technology company. It operates in two segments: Retail Pharmacy Services and Pharmacy Technology. It generates the majority of revenue from the Retail Pharmacy Services segment, which is into operating SpotRx, a full-service retail pharmacy utilizing MedAvail's automated pharmacy technology, servicing Medicare patients in the United States. The Pharmacy Technology segment develops and commercializes the MedCenter for direct sale or lease to third-party customers.
12GF Score

Get the complete analysis for STU:73M

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.05
Price